Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Parathyroid hormone (PTH(1-34)) is used off-label for chronic hypoparathyroidism when standard therapies are insufficient.
• PTH(1-34) effectively controls serum calcium but also stimulates bone remodeling, potentially raising bone turnover markers above normal.
• This study investigates the risk of excessive bone stimulation with prolonged PTH(1-34) treatment.

Purpose of the Study:

• To visually assess the risk of excessive bone stimulation during long-term PTH(1-34) replacement therapy.
• To identify predictors of pathological bone uptake in patients with chronic hypoparathyroidism on PTH(1-34).

Main Methods:

• Observational study of adults with chronic hypoparathyroidism treated with PTH(1-34) for over 2 years.
• Utilized whole-body 99mTc-methylenediphosphonate scintigraphy, biochemical evaluation, and bone mineral density assessment.
• Primary endpoint: proportion of patients with pathological increases in bone tracer uptake.

Main Results:

• 61% of patients (25/41) showed pathological bone uptake despite adequate calcemic control.
• Higher weight-adjusted PTH(1-34) doses, elevated bone remodeling markers, hypomagnesemia, and increased urinary calcium were associated with pathological uptake.
• A predictive score combining bone turnover markers and magnesium achieved 97% classification accuracy.

Conclusions:

• Prolonged PTH(1-34) therapy for chronic hypoparathyroidism is frequently linked to excessive bone remodeling, irrespective of calcemic control.
• Close monitoring is essential, particularly for patients exhibiting elevated bone remodeling markers and hypomagnesemia.
• This highlights the need for careful management to mitigate potential skeletal complications.